Tag:
Generic drugs
Latest Headlines
Latest Headlines
Unhappy with price caps at home, Indian drugmakers eye more U.S. growth
It's no big secret that international drugmakers are miffed at India. Revoking a few drug patents and overriding others will do that. But India's own pharma companies have their own beef with government policy--namely government pricing policies.
South Africa follows India's lead with proposed drug-patent reforms
South Africa plans to revamp its intellectual-property laws to make it more difficult for pharma companies to win protection for new versions of older drugs. The move comes soon after India's top court backed strict requirements for drug patents.
Justices weigh arguments in generic-liability case
How is a generic drug's label different from the drug itself? That was one of the many questions posed yesterday as the generics-liability case had its Supreme Court airing.
Generics dampen US drug spending; payers fear rising specialty costs
It's confirmed: Another study shows that U.S. drug spending dropped ever so slightly last year. The obvious culprit is generic drugs, with major blockbusters such as Pfizer's ($PFE) Lipitor and AstraZeneca's ($AZN) Seroquel IR now facing cheap rivals.
Apotex, Waxman take sides against pharma in Supreme Court generics cases
The Supreme Court is hopping with pharma news these days. As the top U.S. court prepares to hear arguments tomorrow in the big generics-liability case, some key lawmakers in the generics world are balking at the whole federal-preemption idea.
Generic drugmakers concerned over FDA turmoil
Generic drugmakers are feeling a little taken advantage of. They produce 80% of the drugs used in the U.S. Their products are saving federal health programs billions of dollars and they are now helping cover some of the FDA budget through user fees.
Cipla shoots South Africa's Cipla Medpro a better offer
India's Cipla and its namesake in South Africa, Cipla Medpro, may share a moniker but they haven't seen eye-to-eye on what it will take to share ownership.
Fewer generics approved in 2012 but still a banner year
Given all of the lousy earnings reports and patent cliff talk, one might have expected last year to be the biggest ever for getting new generic drugs into the U.S. market. One would be wrong.
Supreme Court to review key generic drug case
Can generics makers be held accountable for design flaws in the drugs they copy? That's the essential question in a case the U.S. Supreme Court has decided to review involving a Takeda Pharmaceutical generics unit.
FTC: Generic-fighting product tweaks violate antitrust laws
The Federal Trade Commission 's campaign for generic drugs has taken a new twist. The agency, long an opponent of "pay for delay" patent settlements, is now taking up the banner against product tweaks that can keep brands protected for years after initial patents expire.
